All In Biotech

Free tool

FAERS Monitor: Cresemba

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207501 or its brand name (Cresemba, Isavuconazonium Sulfate). Reports on generic versions are filed under their own applications.

Reports

3,844

Serious

2,685

70% of reports

Hospitalization

1,236

Death reported

770

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,094
  • death344
  • nausea190
  • drug ineffective173
  • febrile neutropenia151
  • pyrexia150
  • pneumonia142
  • condition aggravated136
  • fatigue127
  • diarrhoea114
  • dyspnoea109
  • product use in unapproved indication106
  • disease progression104
  • drug interaction102
  • vomiting101

Reports by year received

View as table
YearReports
201557
2016250
2017575
2018238
2019269
2020269
2021208
2022250
2023253
2024364
2025520
2026591

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,315 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal15112.510.71,585
off label useSignal1,0946.86.55,682
disease progressionSignal1044.84.0312
drug interactionSignal1023.52.9183
condition aggravatedSignal1362.42.1117
pneumoniaSignal1422.42.0116
pyrexiaSignal1502.42.0120
product use in unapproved indicationSignal1062.31.981
deathSignal3442.22.0229
nausea1901.31.114
vomiting1011.21.03
dyspnoea1091.10.90
diarrhoea1141.00.80
fatigue1270.90.82
drug ineffective1730.70.620

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.